

Peter E Lipsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6839287/publications.pdf>

Version: 2024-02-01

156
papers

19,864
citations

18436

62
h-index

10708

138
g-index

164
all docs

164
docs citations

164
times ranked

17463
citing authors

#	ARTICLE	IF	CITATIONS
1	Deconvoluting the heterogeneity of SLE: The contribution of ancestry. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 12-23.	1.5	11
2	<scp>Patientâ€Reported</scp> Outcome Information Collected from Lupus Patients Using a Mobile Application: Compliance and Validation. <i>ACR Open Rheumatology</i> , 2022, 4, 99-109.	0.9	3
3	Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 632-643.	0.5	17
4	Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
5	Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases. <i>Science Advances</i> , 2022, 8, eabn4776.	4.7	15
6	Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes. <i>Frontiers in Medicine</i> , 2022, 9, 823244.	1.2	1
7	Biological impact of iberdomide in patients with active systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1136-1142.	0.5	13
8	Repositioning drugs for systemic lupus erythematosus. , 2021, , 641-652.		0
9	Machine Learning in Rheumatic Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 60, 96-110.	2.9	22
10	Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway. <i>Scientific Reports</i> , 2021, 11, 7052.	1.6	113
11	Expression of Human Endogenous Retroviruses in Systemic Lupus Erythematosus: Multiomic Integration With Gene Expression. <i>Frontiers in Immunology</i> , 2021, 12, 661437.	2.2	14
12	Current Status of the Evaluation and Management of Lupus Patients and Future Prospects. <i>Frontiers in Medicine</i> , 2021, 8, 682544.	1.2	5
13	Altered expression of genes controlling metabolism characterizes the tissue response to immune injury in lupus. <i>Scientific Reports</i> , 2021, 11, 14789.	1.6	22
14	Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis. <i>Nature Communications</i> , 2021, 12, 4977.	5.8	73
15	Transcriptomics data: pointing the way to subclassification and personalized medicine in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2021, 33, 579-585.	2.0	2
16	Glutathione peroxidase 4â€regulated neutrophil ferroptosis induces systemic autoimmunity. <i>Nature Immunology</i> , 2021, 22, 1107-1117.	7.0	185
17	Reply to: Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 245-245.	3.5	1
18	An introduction to machine learning and analysis of its use in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2021, 17, 710-730.	3.5	37

#	ARTICLE	IF	CITATIONS
19	Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1085-1092.	0.4	1
20	Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase. <i>Journal of Rheumatology</i> , 2020, 47, 605-612.	1.0	3
21	Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. <i>Nature Reviews Rheumatology</i> , 2020, 16, 32-52.	3.5	68
22	The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus. <i>Journal of Autoimmunity</i> , 2020, 110, 102359.	3.0	89
23	Analysis of Trans-Ancestral SLE Risk Loci Identifies Unique Biologic Networks and Drug Targets in African and European Ancestries. <i>American Journal of Human Genetics</i> , 2020, 107, 864-881.	2.6	23
24	Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies. <i>Arthritis Care and Research</i> , 2020, , .	1.5	8
25	Response to the 2020 American College of Rheumatology Guideline for the Management of Gout: Comment on the Article by FitzGerald et al. <i>Arthritis Care and Research</i> , 2020, 72, 1506-1507.	1.5	12
26	Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus. <i>RMD Open</i> , 2020, 6, e001258.	1.8	10
27	New insights into the role of antinuclear antibodies in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2020, 16, 565-579.	3.5	145
28	Antagonizing miR-7 suppresses B cell hyperresponsiveness and inhibits lupus development. <i>Journal of Autoimmunity</i> , 2020, 109, 102440.	3.0	27
29	Development of a multivariable improvement measure for gout. <i>Arthritis Research and Therapy</i> , 2020, 22, 164.	1.6	2
30	Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, S31-S38.	1.6	24
31	Management of Gout in the United States: A Claims-based Analysis. <i>ACR Open Rheumatology</i> , 2020, 2, 180-187.	0.9	10
32	Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus. <i>JCI Insight</i> , 2020, 5, .	2.3	47
33	Evaluation of Proposed Criteria for Remission and Evidence-Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout. <i>ACR Open Rheumatology</i> , 2019, 1, 236-243.	0.9	7
34	Machine learning approaches to predict lupus disease activity from gene expression data. <i>Scientific Reports</i> , 2019, 9, 9617.	1.6	58
35	Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 2136.	2.2	41
36	Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2019, 10, 2512.	2.2	30

#	ARTICLE	IF	CITATIONS
37	Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. Hypertension, 2019, 74, 95-101.	1.3	31
38	Genomic Identification of Low-Density Granulocytes and Analysis of Their Role in the Pathogenesis of Systemic Lupus Erythematosus. Journal of Immunology, 2019, 202, 3309-3317.	0.4	37
39	Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus. Communications Biology, 2019, 2, 140.	2.0	66
40	Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase. Rheumatology, 2019, 58, 1422-1431.	0.9	8
41	Current challenges in the development of new treatments for lupus. Annals of the Rheumatic Diseases, 2019, 78, 729-735.	0.5	39
42	Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials. Arthritis and Rheumatology, 2018, 70, 1450-1458.	2.9	18
43	Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212599.	0.5	98
44	Engaging African ancestry participants in SLE clinical trials. Lupus Science and Medicine, 2018, 5, e000297.	1.1	20
45	Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus. PLoS ONE, 2018, 13, e0208132.	1.1	80
46	Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. Arthritis Research and Therapy, 2018, 20, 286.	1.6	28
47	The Impact of Protein Acetylation/Deacetylation on Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2018, 19, 4007.	1.8	13
48	Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet, The, 2018, 392, 1330-1339.	6.3	244
49	Aberrant Expansion and Function of Follicular Helper T Cell Subsets in IgG4-Related Disease. Arthritis and Rheumatology, 2018, 70, 1853-1865.	2.9	89
50	Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow-up of a randomized, non-blinded, controlled study. Arthritis Research and Therapy, 2018, 20, 70.	1.6	47
51	Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease. Arthritis Research and Therapy, 2017, 19, 25.	1.6	110
52	Mechanisms That Shape Human Antibody Repertoire Development in Mice Transgenic for Human Ig H and L Chain Loci. Journal of Immunology, 2017, 198, 3963-3977.	0.4	20
53	New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti- α -DNA. Arthritis and Rheumatology, 2017, 69, 487-493.	2.9	42
54	Drug Repositioning Strategies for the Identification of Novel Therapies for Rheumatic Autoimmune Inflammatory Diseases. Rheumatic Disease Clinics of North America, 2017, 43, 467-480.	0.8	16

#	ARTICLE	IF	CITATIONS
55	Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. <i>Arthritis Research and Therapy</i> , 2017, 19, 191.	1.6	25
56	Repositioning Drugs for Systemic Lupus Erythematosus. , 2016, , 567-575.		2
57	Beyond pan-B-cell-directed therapy – new avenues and insights into the pathogenesis of SLE. <i>Nature Reviews Rheumatology</i> , 2016, 12, 645-657.	3.5	69
58	Autoregulatory function of interleukin-10-producing pre-naïve B cells is defective in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 190.	1.6	16
59	The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2015, 14, 1079-1086.	2.5	59
60	Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. <i>Rheumatology</i> , 2015, 54, 1982-1990.	0.9	185
61	Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1078-1086.	0.5	189
62	Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. <i>Science Translational Medicine</i> , 2014, 6, 246ra99.	5.8	145
63	Increased Frequency of a Unique Spleen Tyrosine Kinase Bright Memory B Cell Population in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2014, 66, 3424-3435.	2.9	58
64	B cells. <i>Current Opinion in Rheumatology</i> , 2014, 26, 228-236.	2.0	40
65	TwHF versus methotrexate in the treatment of rheumatoid arthritis: response to Landewe's comment on the TRIFRA study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e63-e63.	0.5	2
66	Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. <i>Arthritis Research and Therapy</i> , 2014, 16, R60.	1.6	195
67	SLE Peripheral Blood B Cell, T Cell and Myeloid Cell Transcriptomes Display Unique Profiles and Each Subset Contributes to the Interferon Signature. <i>PLoS ONE</i> , 2013, 8, e67003.	1.1	165
68	Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia. <i>Blood</i> , 2012, 120, 5021-5031.	0.6	43
69	Molecular Characterization of Circulating Plasma Cells in Patients with Active Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2012, 7, e44362.	1.1	54
70	Mechanisms of B cell autoimmunity in SLE. <i>Arthritis Research and Therapy</i> , 2011, 13, 243.	1.6	225
71	Abnormalities of B cell subsets in patients with systemic lupus erythematosus. <i>Journal of Immunological Methods</i> , 2011, 363, 187-197.	0.6	111
72	Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 711.	3.8	433

#	ARTICLE	IF	CITATIONS
73	Analysis of the Stability and Degradation Products of Triptolide. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 52, 3-12.	1.2	21
74	Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. <i>Arthritis and Rheumatism</i> , 2010, 62, 542-552.	6.7	469
75	Competition between TRAF2 and TRAF6 Regulates NF- κ B Activation in Human B Lymphocytes. <i>Chinese Medical Sciences Journal</i> , 2010, 25, 1-12.	0.2	7
76	Identification and Characterization of a Human CD5+ Pre-Naive B Cell Population. <i>Journal of Immunology</i> , 2009, 182, 4116-4126.	0.4	127
77	A polymorphism within <i>IL21R</i> confers risk for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 60, 2402-2407.	6.7	108
78	B cells in autoimmunity. <i>Arthritis Research and Therapy</i> , 2009, 11, 247.	1.6	130
79	Comparison of <i>Tripterygium wilfordii</i> Hook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2009, 151, 229.	2.0	196
80	Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. <i>Arthritis and Rheumatism</i> , 2008, 58, 1762-1773.	6.7	263
81	An Activation-Induced Cytidine Deaminase-Independent Mechanism of Secondary VH Gene Rearrangement in Preimmune Human B Cells. <i>Journal of Immunology</i> , 2008, 181, 7825-7834.	0.4	4
82	The NF- κ B Canonical Pathway Is Involved in the Control of the Exonucleolytic Processing of Coding Ends during V(D)J Recombination. <i>Journal of Immunology</i> , 2008, 180, 1040-1049.	0.4	19
83	Essential Role of IL-21 in B Cell Activation, Expansion, and Plasma Cell Generation during CD4+ T Cell-B Cell Collaboration. <i>Journal of Immunology</i> , 2007, 179, 5886-5896.	0.4	284
84	IL-21 and BAFF/BlyS Synergize in Stimulating Plasma Cell Differentiation from a Unique Population of Human Splenic Memory B Cells. <i>Journal of Immunology</i> , 2007, 178, 2872-2882.	0.4	143
85	Medicinal chemistry and pharmacology of genus <i>Tripterygium</i> (Celastraceae). <i>Phytochemistry</i> , 2007, 68, 732-766.	1.4	367
86	Anti-inflammatory and immunosuppressive compounds from <i>Tripterygium wilfordii</i> . <i>Phytochemistry</i> , 2007, 68, 1172-1178.	1.4	135
87	TRAF6 Regulates Cell Fate Decisions by Inducing Caspase 8-dependent Apoptosis and the Activation of NF- κ B. <i>Journal of Biological Chemistry</i> , 2006, 281, 11235-11249.	1.6	44
88	Identification and characterization of circulating human transitional B cells. <i>Blood</i> , 2005, 105, 4390-4398.	0.6	504
89	Determination of tumor necrosis factor receptor-associated factor trimerization in living cells by CFP-YFP-mRFP FRET detected by flow cytometry. <i>Nucleic Acids Research</i> , 2005, 33, e61-e61.	6.5	48
90	Staphylococcal Protein A Deletes B-1a and Marginal Zone B Lymphocytes Expressing Human Immunoglobulins: An Immune Evasion Mechanism. <i>Journal of Immunology</i> , 2005, 175, 7719-7727.	0.4	30

#	ARTICLE	IF	CITATIONS
91	IL-21 Induces Differentiation of Human Naive and Memory B Cells into Antibody-Secreting Plasma Cells. <i>Journal of Immunology</i> , 2005, 175, 7867-7879.	0.4	580
92	TRAF3 Forms Heterotrimers with TRAF2 and Modulates Its Ability to Mediate NF- κ B Activation. <i>Journal of Biological Chemistry</i> , 2004, 279, 55855-55865.	1.6	76
93	Characterization of the Human Ig Heavy Chain Antigen Binding Complementarity Determining Region 3 Using a Newly Developed Software Algorithm, JOINSOLVER. <i>Journal of Immunology</i> , 2004, 172, 6790-6802.	0.4	120
94	Regulation of B Cell Differentiation and Plasma Cell Generation by IL-21, a Novel Inducer of Blimp-1 and Bcl-6. <i>Journal of Immunology</i> , 2004, 173, 5361-5371.	0.4	588
95	Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals. <i>Arthritis Research</i> , 2004, 6, 28.	2.0	40
96	A flow cytometric method to detect protein-protein interaction in living cells by directly visualizing donor fluorophore quenching during CFP \rightarrow YFP fluorescence resonance energy transfer (FRET). <i>Cytometry</i> , 2003, 55A, 71-85.	1.8	54
97	Correlation between circulating CD27 ^{high} plasma cells and disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003, 48, 1332-1342.	6.7	319
98	New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers. <i>Current Opinion in Rheumatology</i> , 2003, 15, 563-570.	2.0	64
99	How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. <i>Arthritis and Rheumatism</i> , 2002, 47, 215-218.	6.7	132
100	Benefit of an extract of <i>Tripterygium Wilfordii</i> Hook F in patients with rheumatoid arthritis: A double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2002, 46, 1735-1743.	6.7	279
101	Similar T-cell oligoclonality in antimitochondrial antibody-positive and -negative primary biliary cirrhosis. <i>Digestive Diseases and Sciences</i> , 2001, 46, 345-351.	1.1	6
102	Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. <i>Nature Immunology</i> , 2001, 2, 764-766.	7.0	637
103	Lymphoid Chemokine B Cell-Attracting Chemokine-1 (CXCL13) Is Expressed in Germinal Center of Ectopic Lymphoid Follicles Within the Synovium of Chronic Arthritis Patients. <i>Journal of Immunology</i> , 2001, 166, 650-655.	0.4	254
104	Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. <i>Arthritis and Rheumatism</i> , 2000, 43, 4-13.	6.7	273
105	Targeting and selection of mutations in human V λ rearrangements. <i>European Journal of Immunology</i> , 2000, 30, 1597-1605.	1.6	31
106	The response of human B lymphocytes to oligodeoxynucleotides. <i>Seminars in Immunopathology</i> , 2000, 22, 63-75.	4.0	8
107	The V λ Repertoire in Human Fetal Spleen: Evidence for Positive Selection and Extensive Receptor Editing. <i>Journal of Immunology</i> , 2000, 165, 6322-6333.	0.4	32
108	Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2000, 165, 5970-5979.	0.4	564

#	ARTICLE	IF	CITATIONS
109	Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1594-1602.	13.9	2,910
110	Measurement of Human and Murine Interleukin 2 and Interleukin 4. <i>Current Protocols in Immunology</i> , 2000, 37, Unit 6.3.	3.6	5
111	THE CHINESE ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE HERBAL REMEDY TRIPTERYGIUM WILFORDII HOOK F. <i>Rheumatic Disease Clinics of North America</i> , 2000, 26, 29-50.	0.8	261
112	Human CD4+ T cell differentiation and effector function. <i>Immunologic Research</i> , 1999, 19, 25-34.	1.3	9
113	Positive impact of an intervention by arthritis patient educators on knowledge and satisfaction of patients in a rheumatology practice. <i>Arthritis and Rheumatism</i> , 1999, 12, 370-375.	6.7	36
114	Targeting and subsequent selection of somatic hypermutations in the human V β repertoire. <i>European Journal of Immunology</i> , 1999, 29, 3122-3132.	1.6	27
115	Somatic hypermutation of V β J β rearrangements: targeting of RGYW motifs on both DNA strands and preferential selection of mutated codons within RGYW motifs. <i>European Journal of Immunology</i> , 1999, 29, 4011-4021.	1.6	48
116	Effects of tripterygium wilfordii Hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. <i>Arthritis and Rheumatism</i> , 1998, 41, 130-138.	6.7	109
117	Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. <i>Arthritis and Rheumatism</i> , 1998, 41, 1591-1602.	6.7	457
118	Th1/Th2 cytokine balance in arthritis: Comment on the article by Miossec and van den Berg. <i>Arthritis and Rheumatism</i> , 1998, 41, 1896-1897.	6.7	4
119	Comparable impact of mutational and selective influences in shaping the expressed repertoire of peripheral IgM+/CD5 $^+$ and IgM+/CD5 $^+$ B α cells. <i>European Journal of Immunology</i> , 1998, 28, 657-668.	1.6	33
120	Human memory T cell differentiation into Th2-like effector cells is dependent on IL-4 and CD28 stimulation and inhibited by TCR ligation. <i>European Journal of Immunology</i> , 1998, 28, 2517-2529.	1.6	34
121	Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. <i>European Journal of Immunology</i> , 1998, 28, 3384-3396.	1.6	117
122	Deficient interleukin-10 production by neonatal T cells does not explain their ineffectiveness at promoting neonatal B cell differentiation. <i>European Journal of Immunology</i> , 1998, 28, 4248-4256.	1.6	19
123	Similar characteristics of the CDR3 of VH 1-69/DP-10 rearrangements in normal human peripheral blood and chronic lymphocytic leukaemia B cells. <i>British Journal of Haematology</i> , 1998, 102, 516-521.	1.2	24
124	Positive impact of an intervention by arthritis educators on retention of information, confidence, and examination skills of medical students. <i>Arthritis and Rheumatism</i> , 1998, 11, 32-38.	6.7	25
125	Cyclooxygenase in biology and disease. <i>FASEB Journal</i> , 1998, 12, 1063-1073.	0.2	2,208
126	Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. <i>European Journal of Immunology</i> , 1998, 28, 3384-3396.	1.6	1

#	ARTICLE	IF	CITATIONS
127	Satisfaction of patients attending an arthritis clinic in a county teaching hospital. <i>Arthritis and Rheumatism</i> , 1997, 10, 169-176.	6.7	7
128	B Cell Superantigens: Potential Modifiers of the Normal Human BCell Repertoire. <i>International Reviews of Immunology</i> , 1997, 14, 309-324.	1.5	24
129	Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation. <i>Arthritis and Rheumatism</i> , 1997, 40, 639-647.	6.7	39
130	Repeat treatment of Rheumatoid Arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. <i>Arthritis and Rheumatism</i> , 1997, 40, 849-853.	6.7	95
131	Dendritic Cells: Origin and Differentiation. <i>Stem Cells</i> , 1996, 14, 196-206.	1.4	56
132	Presentation of self peptides by dendritic cells. Possible implications for the pathogenesis of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 183-190.	6.7	100
133	A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 1102-1108.	6.7	55
134	Elevated interleukin-10 levels in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 96-104.	6.7	209
135	Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. <i>Arthritis and Rheumatism</i> , 1994, 37, 992-999.	6.7	268
136	Effects of administration of an anti-cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies. <i>Arthritis and Rheumatism</i> , 1993, 36, 620-630.	6.7	86
137	Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 1098-1102.	6.7	95
138	Sjögren's syndrome presenting as hypokalemic periodic paralysis. <i>Arthritis and Rheumatism</i> , 1993, 36, 1735-1738.	6.7	39
139	Regulation of T cell proliferation by anti-CD49d and anti-CD29 monoclonal antibodies. <i>Journal of Leukocyte Biology</i> , 1992, 52, 456-462.	1.5	18
140	Expression and distribution of CD11a/CD18 and CD54 during human T cell-B cell interactions. <i>Journal of Leukocyte Biology</i> , 1992, 52, 97-103.	1.5	16
141	Engagement of class I major histocompatibility complex molecules by cell surface CD8 delivers an activation signal. <i>European Journal of Immunology</i> , 1992, 22, 1379-1383.	1.6	21
142	Regulation of B Cell Function by Lobenzarit, A Novel Disease-Modifying Antirheumatic Drug. <i>Arthritis and Rheumatism</i> , 1992, 35, 168-175.	6.7	7
143	The intrinsic migratory capacity of memory T cells contributes to their accumulation in rheumatoid synovium. <i>Arthritis and Rheumatism</i> , 1992, 35, 1434-1444.	6.7	64
144	Rheumatoid synovium is enriched in CD45RBdim mature memory T cells that are potent helpers for B cell differentiation. <i>Arthritis and Rheumatism</i> , 1992, 35, 1455-1465.	6.7	94

#	ARTICLE	IF	CITATIONS
145	Effect of an Extract of the Chinese Herbal Remedy <i>Tripterygium Wilfordii</i> Hook F on Human Immune Responsiveness. <i>Arthritis and Rheumatism</i> , 1991, 34, 1274-1281.	6.7	117
146	Accessory Cell Signals Involved in T-Cell Activation. <i>Immunological Reviews</i> , 1990, 117, 5-66.	2.8	170
147	Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1990, 33, 19-28.	6.7	61
148	Relationship between clinical efficacy and laboratory correlates of inflammatory and immunologic activity in rheumatoid arthritis patients treated with nonsteroidal antiinflammatory drugs. <i>Arthritis and Rheumatism</i> , 1990, 33, 623-633.	6.7	25
149	The control of antibody production by immunomodulatory molecules. <i>Arthritis and Rheumatism</i> , 1989, 32, 1345-1355.	6.7	40
150	Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1988, 31, 1230-1238.	6.7	246
151	Prostaglandin e2 modulation of rheumatoid factor synthesis. <i>Arthritis and Rheumatism</i> , 1988, 31, 1473-1480.	6.7	8
152	The roles of interleukin 2 and interferon- β in human B cell activation, growth and differentiation. <i>European Journal of Immunology</i> , 1986, 16, 925-932.	1.6	104
153	Functional heterogeneity of human antigen-presenting cells: Presentation of soluble antigen but not self-Ia by monocytes. <i>Journal of Clinical Immunology</i> , 1986, 6, 9-20.	2.0	12
154	IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures. <i>Arthritis and Rheumatism</i> , 1985, 28, 742-752.	6.7	86
155	Inhibition of Human Helper T Cell Function In Vitro by d-Penicillamine and CuSO ₄ . <i>Journal of Clinical Investigation</i> , 1980, 65, 1069-1076.	3.9	124
156	Spontaneous and induced membrane hyperpolarizations in macrophages. <i>Journal of Cellular Physiology</i> , 1975, 86, 653-661.	2.0	118